Astria Therapeutics (NASDAQ:ATXS) Shares Cross Above Fifty Day Moving Average - Here's Why

Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report)'s share price passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $4.79 and traded as high as $6.13. Astria Therapeutics shares last traded at $5.86, with a volume of 470,476 shares.

Wall Street Analyst Weigh In

Several research analysts have issued reports on ATXS shares. HC Wainwright restated a "buy" rating and issued a $16.00 price target on shares of Astria Therapeutics in a research report on Friday, June 13th. Cantor Fitzgerald restated an "overweight" rating and issued a $47.00 price target on shares of Astria Therapeutics in a research report on Wednesday, May 14th. Finally, Wedbush restated an "outperform" rating and issued a $28.00 price target (up previously from $27.00) on shares of Astria Therapeutics in a research report on Wednesday, March 12th. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $30.00.

Astria Therapeutics Trading Down 0.5%

The stock has a market capitalization of $330.68 million, a PE ratio of -3.13 and a beta of 0.39. The firm's 50-day simple moving average is $4.79 and its two-hundred day simple moving average is $6.44.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.10). As a group, research analysts expect that Astria Therapeutics, Inc. will post -1.65 earnings per share for the current year.

Hedge Funds Weigh In On Astria Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Rhumbline Advisers lifted its stake in shares of Astria Therapeutics by 2.3% in the 4th quarter. Rhumbline Advisers now owns 62,163 shares of the biotechnology company's stock valued at $556,000 after purchasing an additional 1,381 shares during the last quarter. New York State Common Retirement Fund increased its holdings in shares of Astria Therapeutics by 67.0% during the 4th quarter. New York State Common Retirement Fund now owns 10,720 shares of the biotechnology company's stock worth $96,000 after purchasing an additional 4,300 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Astria Therapeutics by 2.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 322,576 shares of the biotechnology company's stock valued at $2,884,000 after acquiring an additional 8,311 shares during the period. Raymond James Financial Inc. bought a new stake in Astria Therapeutics in the fourth quarter valued at about $707,000. Finally, Swiss National Bank boosted its position in Astria Therapeutics by 13.1% in the fourth quarter. Swiss National Bank now owns 66,600 shares of the biotechnology company's stock valued at $595,000 after buying an additional 7,700 shares in the last quarter. 98.98% of the stock is currently owned by hedge funds and other institutional investors.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.